{"name":"Hisamitsu Pharmaceutical Co., Inc.","slug":"hisamitsu-pharmaceutical-co-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"1975-01-01","label":"Ditropan Xl first approved","drug":"Ditropan Xl","drugSlug":"oxybutynin","type":"approval","sentiment":"positive"},{"date":"1988-01-01","label":"Voltaren first approved","drug":"Voltaren","drugSlug":"diclofenac","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"HKT-500 Topical Patch","genericName":"HKT-500 Topical Patch","slug":"hkt-500-topical-patch","indication":"Other","status":"phase_2"},{"name":"FS-67 Patch","genericName":"FS-67 Patch","slug":"fs-67-patch","indication":"Other","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Voltaren","genericName":"DICLOFENAC","slug":"diclofenac","indication":"Actinic keratosis","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Ditropan Xl","genericName":"OXYBUTYNIN","slug":"oxybutynin","indication":"Bladder muscle dysfunction - overactive","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"HKT-500 Ketoprofen Topical Patch","genericName":"HKT-500 Ketoprofen Topical Patch","slug":"hkt-500-ketoprofen-topical-patch","indication":"Localized musculoskeletal pain and inflammation","status":"phase_3"}]}],"pipeline":[{"name":"Voltaren","genericName":"DICLOFENAC","slug":"diclofenac","phase":"marketed","mechanism":"Prostaglandin G/H synthase 2","indications":["Actinic keratosis","Adhesive capsulitis of shoulder","Analgesia in various types of cancer","Ankylosing spondylitis","Dysmenorrhea"],"catalyst":""},{"name":"HKT-500 Topical Patch","genericName":"HKT-500 Topical Patch","slug":"hkt-500-topical-patch","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ditropan Xl","genericName":"OXYBUTYNIN","slug":"oxybutynin","phase":"marketed","mechanism":"Oxybutynin works by blocking the action of a chemical called acetylcholine on the bladder muscle, reducing spasms and urgency.","indications":["Bladder muscle dysfunction - overactive","Hyperhidrosis of palms","Increased Urinary Frequency","Neurogenic bladder","Urge incontinence of urine"],"catalyst":""},{"name":"FS-67 Patch","genericName":"FS-67 Patch","slug":"fs-67-patch","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HKT-500 Ketoprofen Topical Patch","genericName":"HKT-500 Ketoprofen Topical Patch","slug":"hkt-500-ketoprofen-topical-patch","phase":"phase_3","mechanism":"Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain.","indications":["Localized musculoskeletal pain and inflammation","Osteoarthritis pain (topical)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTFB2aHNablhFTzFzUXctVVlhUUItTU9iWVVOOHNSZDFHTV80MUJPcGZEUUxjSXZEV0kxYnc5bXVIclBtaGFJYk5BeEM3U2VWdVczcDhDLVNnUkFHZldaX3NwaG5ZWFMtYmo0b0JSdHRWOUhhNHlkdzlCLVNHWQ?oc=5","date":"2026-01-16","type":"pipeline","source":"Straits Research","summary":"Non-Opioid Pain Patches Market Size, Share & Growth Graph by 2034 - Straits Research","headline":"Non-Opioid Pain Patches Market Size, Share & Growth Graph by 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQZ3M2dmlfVEo3d2NSX0ZoQ2k3djdCdlRLdzk1eGotT2RkdnVqQU1pb25WMzFEX3NlMjJ2M3BXMFNuZnNvdGt6T2NTRmozYW5HdUVCWVVwZjJaWjdUSWVzOXotd1FhWE54V3o0QXFMQy01YUtoZE9sdWxzZEZfa0lTSGRjQUtLQzlYM2ktUnpQQlZZVUdKLVE?oc=5","date":"2026-01-09","type":"deal","source":"BioWorld News","summary":"Hisamitsu to go private with $2.5B management buyout - BioWorld News","headline":"Hisamitsu to go private with $2.5B management buyout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOT1hTVnZreC1XUWg0Z29KdkdXazVHUmEwNFRoaG1KRHZaRFRoMzFIeUVDME5wSzRPV0EzTUMtX0N3NGljQVNmMy1lZEdfSHAwb0Ffd3dGQThwZHJmRnBXQTMtNVFrd1hNM2ZzMG0zY0FFdC1Yai0wal95MWxzVW5idHdKWGhBc01Td0NDN0Rsdm5sR1ZrZkQxMFNtWU1DWWNWVUswU2JlbFB4bURxb0Z6Yw?oc=5","date":"2026-01-07","type":"deal","source":"Bloomberg.com","summary":"Buyout Wave Seen Among Japan Drugmakers After Hisamitsu Deal - Bloomberg.com","headline":"Buyout Wave Seen Among Japan Drugmakers After Hisamitsu Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPaEF3UDQ3Q1R4S3dDSlloYUVVYk5XNnVBQzdnZVdfZlQtQmtITVZISkR5SlZrcUNmZmN6akhCSEVXZnowUnphWjRRaS1CS0RySklhYW8zMXZmQUZ2NDZ4b2UxRlRJNHRyVTFhZTQzYXRSRDd1TE5WZUp4NVVXNHVObEdFVFkwZ202aTlHdjFEcE1ldHhQbzZ6d2lNNzNIbF9rZ3Q1bGRZMlJCTWE5N2VvQmx5R3hqdDJCSi1FVWlNOGVpeVE?oc=5","date":"2026-01-06","type":"pipeline","source":"Reuters","summary":"Japan's Hisamitsu Pharmaceutical plans $2.55 billion MBO - Reuters","headline":"Japan's Hisamitsu Pharmaceutical plans $2.55 billion MBO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPVVVyTExpQlh2N0UyVzQ1aXVWZmxxV1h2Y0FDXy1xeUpBdC00MUFGdXNhOFhxY3pBWDdYZWwybWpVdVBycHZsdEI3eHBjSXZjZXIzSnM3Z3ZQUEt1R3ZQa05zNlN1c0xwWDhfSkhrTG1Zc0Q4bEh5ZGxad1d2RzZ0XzlPeUNnNXlLcUN3Qmt3SU8xRkRkS1JpcVNaMjQwY2wzcEozN2JVU0tPaFQ1SjVDN3dhV1FlUkVFQzY3NQ?oc=5","date":"2026-01-06","type":"pipeline","source":"Bloomberg.com","summary":"CEO of Salonpas Maker Seeks to Take the $2.9 Billion Drug Firm Private - Bloomberg.com","headline":"CEO of Salonpas Maker Seeks to Take the $2.9 Billion Drug Firm Private","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNNVJIT09uendORkpVSU1lOW0yejNBLXlFdmd4dmEwRjlZaTZvMm1FNFUzSWI5VGdnZVN2eC1JQlUyS2VQN1RrcWRjNGhIb3hCX0FOSmFOTnVkNmkwemN2VlUwa0ZVWUd2WC1JLWZ3RzJSdV82cVJqNjZjaW1WU3JKQQ?oc=5","date":"2025-12-15","type":"regulatory","source":"Fact.MR","summary":"Demand for Transdermal Skin Patches in USA | Global Market Analysis Report - 2035 - Fact.MR","headline":"Demand for Transdermal Skin Patches in USA | Global Market Analysis Report - 2035","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxOQ0hSRGpsbjlPdGpFeWdxc090QVFVNDQtQ1NLcmVuNHBwaUZab0ZaQVI3alVPSGtLTFk2TmtjWEExUDM3Mno0VlFCbUZGSlZOOTJNLWxCa2QxSllPd2lQOHFRUnZtRUY2R3k1MzJQOW9MWUJ2Z1gxcEFlbEdlSFFacjdHS3MyUV9KVjNuVQ?oc=5","date":"2025-04-09","type":"trial","source":"Yahoo Finance","summary":"Sodium Channel Blockers Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight - Yahoo Finance","headline":"Sodium Channel Blockers Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Developing Drugs for Mark","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxQU29HeWJraDVkUEVCTjB5SC0tbERSd2NDMDByYllGeU9KcVU5U2djZFpubzhiamNWdHluMGZoLWRCYjA3XzYwYXQ3SWhCN2UyS0tMMFltRU5MMmYzT18wOFpKenV2QmQwclRxd3lCWkliYW9rTXdHdjNPTkVjYnhNcnV3ckppREJlQzFDZ183UUFGMFRVTGNRSktpa2dRUzN2eVRTYk1Vbm9CRXBTUDF0R2YzWXdpb29kV3MyRklnY1ZMN1hZTnpsZmZmMmRzNk1kSjZkZ3BFeFFDMHdm?oc=5","date":"2025-01-14","type":"pipeline","source":"businesswire.com","summary":"Noven Debuts Optional Companion App for Patients with ADHD – Mindful Patch – at APSARD 2025 - businesswire.com","headline":"Noven Debuts Optional Companion App for Patients with ADHD – Mindful Patch – at APSARD 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQbVp2bjJYQi1ycmU4QTR5RVR6eTlvZ0NTTXNBNU8ySndFQ19DYW1yamhWN2h4bTJRa2NSTTMtSGYwaEtDa3BwWGlwYzZOT0tYbDVHOVI0UldjaDRIVk5VZ3FRRlBMUHdfZjRkSlB5bG03aU4xd2pUTE1FYlpIVk5zaXoyRi1mUHRKQV9uaQ?oc=5","date":"2024-09-03","type":"pipeline","source":"Grand View Research","summary":"The United States Topical Drugs Market Size & Outlook, 2030 - Grand View Research","headline":"The United States Topical Drugs Market Size & Outlook, 2030","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQclN4eEtwZFNFOUtHUVd6N0xSS2lxaDlhX09ZRGVQbVpqZlk3eHU5YmVZd3cydDNoTnZSRllHZ1dNbzVLX0FhdUZzMURzQ3VGck1yLUtic3N3VWN2YThIbjhBYVhRTVR2c3Q5VEZoQWkyYTNKRHFzVzJVWnpuREN3REtrRDVzQk5GZTV6SExuZDZkV0FZa0VPRy1vY1Izck9YRlZOdVhWaUphYWM5MjN4MlJnSkRyekFtQmQySVRwdE83UFk?oc=5","date":"2022-11-10","type":"pipeline","source":"prnewswire.com","summary":"NOVEN TO PARTICIPATE IN ANNUAL INTERNATIONAL CONFERENCE ON ADHD (CHADD) - prnewswire.com","headline":"NOVEN TO PARTICIPATE IN ANNUAL INTERNATIONAL CONFERENCE ON ADHD (CHADD)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQS3FnRDVIcHItTzZrYXc2RGFLYXl3anNNZkFrb0p4VURYa3A4cHZQSmxJRGVGRlkxMlY4aG1lRi1zWUN4SnFTTlEwSm5rZG9ISktrdmlRM3VGNFVXUFNJckJTQ0xLLUdRQmFnLS1ncVY1NnFlR0FESXVsbkpIdWhzNi1DSlFGb0o3RTEyTm5xSkpUMWRRdElzWGFHWUxaRmo1TmZ6ejlWSVR5UQ?oc=5","date":"2021-03-01","type":"pipeline","source":"Pharmacy Times","summary":"Hisamitsu America Announce Launch of Salonpas Arthritis Pain Relief Gel - Pharmacy Times","headline":"Hisamitsu America Announce Launch of Salonpas Arthritis Pain Relief Gel","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE5XbjJWRjA2ZUxIdnUzT2ZObk96Y2Y1S3dfdV90TjRvbU81ZkV1S0xkdHprV0xva2NaNFdFSEVqcHItemlvdjhDamdPSmJhUVUyTnRWNnRfeHY?oc=5","date":"2017-07-26","type":"pipeline","source":"TradingView","summary":"4530 Stock Price and Chart — TSE:4530 - TradingView","headline":"4530 Stock Price and Chart — TSE:4530","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"marketed":3,"phase_2":1,"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}